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Letter to the Editor
Is RARS-T a new disease entity 
or a subtype of RARS or ET?
TO THE EDITOR:  A recent report of “JAK2 V617F mutation in 
myelodysplastic syndrome, myelodysplastic syndrome/myelo-
proliferative neoplasm, unclassifiable, refractory anemia with 
ring sideroblasts with thrombocytosis, and acute myeloid leuke-
mia” by Jekarl DW et al. [1] has shown one patient with 
JAK2 V617F mutation among 7 patients with RARS-T. This 
14.3% of JAK2 mutation rate seems to be lower than 58% 
of previously reported data in the review of Wardrop D 
and Steenma DP [2]. Fifty-four patients had JAK2 mutation 
among 93 patients with RARS-T in 10 serial studies. 
Additionally 2 of 27 JAK2 wild-type patients showed 
MPL
W515 mutation. MPL
W515 mutation is found in 5% of 
primary myelofibrosis and 1% of essential thrombocythemia 
(ET) cases [3]. But Jekarl DW et al did not report about 
this second mutation in their article. One more concern 
for this report was the incidence and the diagnosis of 
RARS-T. Seven patients were enrolled in this single-center 
study only for 3 years. Seven RARS-T patients seemed to 
be extraordinarily many, even when authors used WHO 
2008 criteria which alleviates the criterion of thrombocy-
tosis from 600,000/μL to 450,000/μL, and their center is 
one of the large tertiary hospitals in Korea. Also, there 
was no data on 7 RARS-T patients about the percentages 
of ring sideroblast (RS), and comorbidities which are neces-
sary for the exclusion of other reacitve thrombocytoses such 
as inflammation or bleeding.
  The role of RS in the pathophysiology of RARS, RARS-T 
and RCMD-RS (this entity is recently combined with RCMD 
in WHO 2008 criteria) is not clearly elucidated now. Also 
the cut-off value of 15% is thought to be arbitrary. 
Seventy-three MDS patients with RS showed the wide range 
of RS between 1% and 86% [4]. The survival of patients 
with RARS-T was similar to that of patients with ET but 
better than that of patients with RARS [5]. The thrombohe-
morrhagic complications of patients with RARS-T had not 
been reported except in some case repots. The recommended 
approach to RARS-T is same as in ET although anemia 
and neutropenia could be aggravated by cytoreductive 
therapy. Therefore, RARS-T, a provisional and new entity 
in WHO 2001 and 2008 criteria should be reconsidered 
whether it will be kept its own entity or be integrated 
into ET or RARS as a subtype depending on the dysplastic 
features of marrow.
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THE AUTHORS’ REPLY: Dr. Bang suggested that the in-
cidence of JAK2 V617F mutation in RARS-T was lower 
(14.3%) than previously reported (58%) and MPL mutation 
study was not performed. In case of RARS-T, the enrolled 
period of patients was from January 1999 to February 2010. 
We have found that the sentence written above was omitted 
and we are sorry for the mistake. As the number of patients 
was only 7, larger number of enrolled participant is required 
for the exact incidence as there were no data pertaining 
to Korean and Asian. Ethnic variation could be a possible 
explanation of the different incidence from previous 
publications. In this study, the method used for the detection 
of JAK2 V617F mutation was the real time PCR by melting 
curve analysis which has detection limit of less than 1%. 
As the methods used in previous studies were various, there 
might have been differences in the detection limits of allele 
burden among the methods. However, because myelodys-
plastic syndrome (MDS) and myelodysplastic syn-
drome/myeloproliferative neoplasm (MDS/MPN) are hema-
topoietic stem cell diseases and the possibility of less than 
1% of affected cells at the time of initial diagnosis is theoret-
ically very low. The MPL gene mutational study was per-
formed in 4 of the RARS-T patients with available DNA 
and the results showed that none of them harbored MPL 
exon 10 mutation. Additional studies for the associated genes 
are considered for further evaluation.
  The diagnosis of RARS-T was defined according to the 
following WHO criteria [1]. The number of ring sideroblasts 
of 7 patients was from 21% to 68%. As of comorbidities, 
one patient had diabetes mellitus with dilated cardiomyop-
athy and another patient had subclinical hypothyroidism. 
Because all patients had no written history of diseases caus-
ing thrombocytosis, the reactive thrombocytosis could be 
ruled out. None of the patients had bleeding or thrombotic 
complications.
  We agree with the idea that RARS-T should be reconsid-
ered whether it will be kept its own entity or be integrated 
into ET or RARS as a subtype depending on the dysplastic 
features of marrow. In our cases, only the case with JAK2 
V617F mutation showed platelet counts of more than 
1,000×10
9/L and leukocytosis of 26.95×10
9/L with neutro-
philia and the megakaryocytes showed atypical morphology 
of essential thrombocythemia (ET).
  At least the RARS-T cases with the platelet count of 
greater than 1,000×10
9/L or JAK2 V617F mutation should 
be included in ET rather than in RARS-T. Such cases could 
be classified as ET with ringed sideroblasts (ET-RS).
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